Literature DB >> 3582477

Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose.

J J Crowley, J R Koup, B J Cusack, T M Ludden, R E Vestal.   

Abstract

A large clinical study, designed to investigate the induction of theophylline metabolism by phenytoin, provided the opportunity to test a previously proposed method for estimating dose requirements of phenytoin. This method involves prediction of the oral maintenance dosage from data obtained following the administration of an intravenous loading dose. In 30 subjects, trough plasma concentration at steady-state were 12.0 +/- 4.9 micrograms X ml-1 (mean +/- SD) and differed by -2.7 +/- 39.3% from a mean target plasma concentration of 12.5 +/- 1.5 micrograms X ml-1. A Bayesian regression programme was used to forecast an estimate of each subject's individual pharmacokinetics. These were then used to predict the steady-state plasma concentrations which would be expected from a standard dosing regimen (4 mg per kg per day). When compared to the results expected from the use of this standard dosage, the proposed method gave acceptable steady-state plasma phenytoin concentrations with significant reductions in deviations from target concentrations. This method for the rapid individualization of phenytoin dosage requirements provides an improvement over more traditional methods of choosing an arbitrary dose adjusted for body weight followed by dosage adjustments based on achieved plasma concentration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3582477     DOI: 10.1007/bf00542186

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Nonlinear assessment of phenytoin bioavailability.

Authors:  W J Jusko; J R Koup; G Alván
Journal:  J Pharmacokinet Biopharm       Date:  1976-08

2.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients.

Authors:  R J Sawchuk; D E Zaske
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

3.  Renal function and therapeutic concentrations of phenytoin.

Authors:  D F Liponi; M E Winter; T N Tozer
Journal:  Neurology       Date:  1984-03       Impact factor: 9.910

Review 4.  Enzyme immunoassays in clinical chemistry: present status and trends.

Authors:  M Oellerich
Journal:  J Clin Chem Clin Biochem       Date:  1980-04

5.  Single point estimation of phenytoin dosing: a reappraisal.

Authors:  J R Koup; M Gibaldi; W Godolphin
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1981-11

6.  Predicting individual phenytoin dosage.

Authors:  S Vozeh; K T Muir; L B Sheiner; F Follath
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

7.  Numerical integration simulation programs for the microcomputer.

Authors:  J R Koup; D R Benjamin
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

8.  Steady-state pharmacokinetics of phenytoin from routinely collected patient data.

Authors:  T H Grasela; L B Sheiner; B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens; T Ishizaki; K Chiba
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

9.  Evaluation of a Bayesian regression-analysis computer program for predicting phenytoin concentration.

Authors:  T M Ludden; S L Beal; C C Peck; P J Godley
Journal:  Clin Pharm       Date:  1986-07
  9 in total
  10 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 3.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  Evaluation of a bayesian pharmacokinetic program for phenytoin concentration predictions in outpatient population.

Authors:  J M Gaulier; R Boulieu; C Fischer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

5.  Phenytoin dosage predictions in paediatric patients.

Authors:  G J Yuen; P T Latimer; L C Littlefield; R W Mackey
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

Review 6.  An updated comparison of drug dosing methods. Part I: Phenytoin.

Authors:  R D Pryka; K A Rodvold; S M Erdman
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

7.  Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients.

Authors:  Andrea Tobler; Stefan Mühlebach
Journal:  Int J Clin Pharm       Date:  2013-06-29

Review 8.  Pharmacokinetic optimisation of anticonvulsant therapy.

Authors:  A H Thomson; M J Brodie
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

Review 9.  Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring.

Authors:  Dion R Brocks; Dalia A Hamdy
Journal:  Res Pharm Sci       Date:  2020-11-27

10.  Variability of serum phenytoin levels in critically ill head injured patients in intensive care unit.

Authors:  Lalitha V Pillai; Narendra Vaidya; A D Khade; Saiffuddin Hussainy
Journal:  Indian J Crit Care Med       Date:  2008-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.